Patients with atrial fibrillation undergoing percutaneous coronary intervention. Part I

Mikhail S. Dzeshka, Richard A. Brown, Gregory Y.H. Lip

Full article

A PDF of the full version of the article, published in Polish Archives of Internal Medicine, can be accessed free of charge here.


Atrial fibrillation (AF) and coronary artery disease (CAD) often coexist. Both conditions confer an increased risk of acute thrombotic complications. However, the pathogenesis of thrombus development in AF and CAD is different. Coagulation activation is the main pathway in AF, and platelet activation is the hallmark of coronary thrombosis. Antithrombotic prophylaxis is essential in both conditions.

In patients with AF undergoing percutaneous coronary intervention (PCI), a combination of oral anticoagulation and antiplatelet therapy is required, which elevates the risk of major bleeding. This has to be balanced against the risk of stroke and stent thrombosis. In the first part of the present review, the prerequisites for antithrombotic management in AF patients undergoing PCI are discussed. We cover the epidemiology of concomitant presentation of AF and CAD as well as differences in the pathogenesis of thrombus formation in both conditions. We evaluate data regarding a variety of antithrombotic regimens including triple therapy in line with stroke and bleeding risk assessment.

Overall, triple therapy is often warranted but should be used for the shortest possible duration. Although much of the current guidance comes from observational data, well-designed and adequately powered randomized clinical trials are emerging to further inform practice in this challenging area.

We would love to hear from you

Comments, mistakes, suggestions?


Industry Partners

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.